Biweekly enzyme replacement therapy demonstrates efficacy in pediatric and adult hypophosphatasia while offering lower injection frequency.

Approvals for spinal muscular atrophy and chronic kidney disease; Joenja gains expanded approval in APDS; LSD derivative earns Breakthrough status to treat major depressive disorder; and zasocitinib ...

Phase 3 CELESTIMO study demonstrates significant progression free survival benefit for an mosunetuzumab combination regimen ...

Approval of the nonsteroidal mineralocorticoid receptor antagonist provides the first new treatment option in over 30 years ...

Results from the final ORIGIN 3 analysis reveal that atacicept over 104 weeks significantly reduced the risk of a composite ...

About 1.4 million Americans seek medical care after animal contact each year and roughly 100,000 receive rabies shots. Fewer than 10 people die. The CDC advises keeping away from wildlife, keeping ...

All participating US comprehensive cancer centers report a shortage of at least 1 drug with 20% reporting 5 or more medications in short supply.

Transferrin saturation and ferritin thresholds recommended for guiding iron therapy; IV iron preferred over oral iron for hemodialysis recipients.

Anifrolumab monotherapy associated with lower odds of hospitalization and antibiotic use compared with conventional immunosuppressants ...

Gap is 5.6 years shorter than the overall Medicaid population and 13.8 years shorter than the US general population.

Results from the final ORIGIN 3 analysis reveal that atacicept over 104 weeks significantly reduced the risk of a composite kidney disease progression event by 76% in adults with primary IgA ...

Phase 3 COVER DFUS II trial data show the autologous therapy plus standard of care significantly improves wound closure rates ...